One of the latest companies to hit the public market is Caris Life Sciences (CAI). Pricing its IPO at $21 per share, Caris ...

The stock of Caris Life Sciences shined in its Nasdaq debut on Wednesday, pricing its heavily-subscribed initial public ...

The cancer diagnostics and treatment company priced shares above their earlier target range and might signal a renewed ...

Caris Life Sciences® (Caris), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, ...

Caris Life Sciences Inc., a health-care company that uses technology to help diagnose and treat cancer, raised $494 million ...

Caris Life Sciences Inc., a health care company that uses technology to help diagnose and treat cancer, raised $494 million ...

David Dean Halbert, Caris Life Sciences chairman, founder and CEO, joins 'Squawk Box' to discuss the company's IPO debut, how ...

The successful IPO of Caris Life Sciences makes its founder David Dean Halbert worth an estimated $3.3 billion.

Cancer-testing company raises $494 million in initial public offering.

Caris Life Sciences bumped up the pricing of its IPO to raise more than $494.1 million in its Nasdaq debut—well over the ...

Caris Life Sciences is experiencing rapid growth, leveraging AI and molecular science for personalized medicine. Click here ...

Caris Life Sciences raised $494.1 million in its Nasdaq initial public offering, the cancer diagnostic firm said on Tuesday, ...